Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 1961-1967

  Topalis, D ^a   Lebeau, I ^a   Krecmerova M ^b   Andrei, G ^a   Snoeck, R ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 5 AZACYTOSINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL]GUANINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 2,6 DIAMINOPURINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL]ADENINE; ACYCLIC NUCLEOSIDE; ADEFOVIR; CIDOFOVIR; CYCLIC 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL]ADENINE; CYCLIC CIDOFOVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BK VIRUS; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; KIDNEY CELL; NONHUMAN; PRIORITY JOURNAL; RENAL CORTICAL EPITHELIAL CELL; RENAL PROXIMAL TUBULAR EPITHELIAL CELL; VIRUS REPLICATION;

BK VIRUS; CELL LINE; CELL PROLIFERATION; CYTARABINE; CYTOSINE; HUMANS; ISOXAZOLES; KIDNEY; NUCLEOSIDES; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION; VIDARABINE;

EID: 79955541736     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01809-10     Document Type: Article

References (48)

1. Allander, T., et al. 2007. Identification of a third human polyomavirus. J. Virol. 81:4130-4136. (Pubitemid 46586907)
2. Andrei, G., et al. 2007. Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient. Transpl. Infect. Dis. 9:126-131.
3. Andrei, G., R. Snoeck, M. Vandeputte, and E. De Clercq. 1997. Activities of various compounds against murine and primate polyomaviruses. Antimicrob. Agents Chemother. 41:587-593.
4. Astrom, K. E., E. L. Mancall, and E. P. Richardson. 1958. Progressive multifocal leukoencephalopathy - a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81:93-111.
5. Bartt, R. E. 2006. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 19:341-349.
6. Bernhoff, E., T. J. Gutteberg, K. Sandvik, H. H. Hirsch, and C. H. Rinaldo. 2008. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am. J. Transplant. 8:1413-1422.
7. Cihlar, T., and M. S. Chen. 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50:1502-1510.
8. Cinque, P., I. J. Koralnik, S. Gerevini, J. M. Miro, and R. W. Price. 2009. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect. Dis. 9:625-636.
9. Cundy, K. C., et al. 1995. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39:1247-1252.
10. Daniels, R., D. Sadowicz, and D. N. Hebert. 2007. A very late viral protein triggers the lytic release of SV40. PLoS Pathog. 3:928-938.
11. De Clercq, E. 2007. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res. 75:1-13. (Pubitemid 46610520)
12. De Luca, A., et al. 2008. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 22:1759-1767.
13. De Luca, A., et al. 2000. Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 14:F117-F121.
14. Feng, H., M. Shuda, Y. Chang, and P. S. Moore. 2008. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319:1096-1100.
15. Gaynor, A. M., et al. 2007. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog. 3:e64.
16. Gheuens, S., G. Pierone, P. Peeters, and I. J. Koralnik. 2010. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J. Neurol. Neurosurg. Psychiatry 81:247-254.
17. Hartung, H. P. 2009. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol. 8:28-31.
18. Herman, J., et al. 2004. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. Pediatr. Transplant. 8:485-492.
19. Hirsch, H. H., et al. 2005. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79:1277-1286. (Pubitemid 40734783)
20. Hirsch, H. H., et al. 2002. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N. Engl. J. Med. 347:488-496.
21. Houben, R., et al. 2010. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J. Virol. 84:7064-7072.
22. Johnston, O., et al. 2010. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 89:1057-1070.
23. Kappos, L., et al. 2007. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 6:431-441. (Pubitemid 46551850)
24. Kean, J. M., S. Rao, M. Wang, and R. L. Garcea. 2009. Seroepidemiology of human polyomaviruses. PLoS Pathog. 5:e1000363.
25. Kuypers, D. R., et al. 2005. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am. J. Transplant. 5:1997-2004.
26. Langer-Gould, A., S. W. Atlas, A. J. Green, A. W. Bollen, and D. Pelletier. 2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353:375-381.
27. Lebeau, I., et al. 2007. Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains. Antimicrob. Agents Chemother. 51:2268-2273.
28. Leung, A. Y., K. Y. Yuen, and Y. L. Kwong. 2005. Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm. Bone Marrow Transplant. 36:929-937.
29. Levine, A. J. 2009. The common mechanisms of transformation by the small DNA tumor viruses. The inactivation of tumor suppressor gene products: p53. Virology 384:285-293.
30. Ludlow, J. W. 1993. Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB J. 7:866-871. (Pubitemid 23225542)
31. Magee, W. C., K. Y. Hostetler, and D. H. Evans. 2005. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 49:3153-3162.
32. Major, E. O. 2010. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61:35-47.
33. Naess, H., et al. 2010. Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurol. 10:32.
34. Paborsky, L. R., C. T. Mao, P. Kramata, M. L. Compton, and J. J. Toole. 1997. Potent anti-proliferative activity of a novel nucleotide analogue, PMEG, against human solid tumor cell lines. Proc. Am. Assoc. Cancer Res. 38:100.
35. Randhawa, P. S., and A. J. Demetris. 2000. Nephropathy due to polyomavirus type BK. N. Engl. J. Med. 342:1361-1363.
36. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
37. Robbins, B. L., M. C. Connelly, D. R. Marshall, R. V. Srinivas, and A. Fridland. 1995. A human T-lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Mol. Pharmacol. 47:391-397.
38. Roberts, M. T. M., A. Carmichael, and A. M. L. Lever. 2003. Prolonged survival in AIDS-related progressive multifocal leucoencephalopathy following anti-retroviral therapy and cidofovir. Int. J. Antimicrob. Agents 21:347-349.
39. Rose, W. C., A. R. Crosswell, J. J. Bronson, and J. C. Martin. 1990. In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]-guanine and related phosphonate nucleotide analogues. J. Natl. Cancer Inst. 82:510-512.
40. Savona, M. R., et al. 2007. Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant. 39:783-787. (Pubitemid 46901977)
41. Snoeck, R., and E. De Clercq. 2002. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr. Opin. Invest. Drugs 3:1561-1566.
42. Stahl, H., P. Droge, and R. Knippers. 1986. DNA helicase activity of SV40 large tumor-antigen. EMBO J. 5:1939-1944.
43. Van Assche, G., et al. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353:362-368.
44. van der Meijden, E., et al. 2010. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog. 6:e1001024.
45. Wolfgang, G. H., et al. 2009. GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions. Antimicrob. Agents Chemother. 53:2777-2784.
46. Wu, J. K., and M. T. Harris. 2008. Use of leflunomide in the treatment of polyomavirus BK-associated nephropathy. Ann. Pharmacother. 42:1679-1685.
47. Xiong, X. F., J. L. Smith, and M. S. Chen. 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41:594-599.
48. Xiong, X. F., J. L. Smith, C. Kim, E. S. Huang, and M. S. Chen. 1996. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem. Pharmacol. 51:1563-1567.